EP Patent

EP3965830A1 — Differentially expressed immune cell micrornas for regulation of protein expression

Assigned to ModernaTx Inc · Expires 2022-03-16 · 4y expired

What this patent protects

The disclosure features mRNAs engineered with one or more microRNA binding sites targeted by a microRNA(s) that are differentially expressed in a target immune cell relative to a plurality of non-target immune cells. The disclosure also features methods of using the same, for exa…

USPTO Abstract

The disclosure features mRNAs engineered with one or more microRNA binding sites targeted by a microRNA(s) that are differentially expressed in a target immune cell relative to a plurality of non-target immune cells. The disclosure also features methods of using the same, for example, for selectively degrading the mRNA in the target immune cell relative to the plurality of non-target immune cells.

Drugs covered by this patent

Patent Metadata

Patent number
EP3965830A1
Jurisdiction
EP
Classification
—
Expires
2022-03-16
Drug substance claim
No
Drug product claim
No
Assignee
ModernaTx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.